Research programme: anticancer monoclonal antibodies - Morphotek

Drug Profile

Research programme: anticancer monoclonal antibodies - Morphotek

Alternative Names: Humanised mAbs for cancer - Morphotek/National Cancer Institute (NCI); MORAb-050

Latest Information Update: 08 Jul 2013

Price : $50

At a glance

  • Originator Morphotek
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Malignant melanoma

Most Recent Events

  • 08 Jul 2013 Preclinical trials of MORAb 050 in Malignant melanoma (metastatic disease) in USA (Parenteral)
  • 25 May 2010 Preclinical development is ongoing in the US
  • 04 Jul 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top